2013


To access this material please log in or register

Register Authorize
2013/№2

Evaluation of the syndrome of acute decompensated heart failure and concomitant diseases in patients residing in the Bashkortostan Republic

Shepel R. N., Zakirova A. N.

Keywords: acute decompensated heart failure, Republic of Bashkortostan, epidemiology



DOI: 10.18087 / rhfj.2013.2.1781

Background. Acute decompensated CHF (ADCHF) should be regarded as an independent syndrome resulting from chronic cardiovascular disease. ADCHF is evident as aggravated/emerging dyspnea, edema, weakness and anxiety. Aim. Studying the prevalence, etiology, and duration of hospitalization for CHF with the ADCHF syndrome and concomitant diseases among residents of the Bashkortostan Republic and analyzing the administered therapy and therapeutic tactics. Materials and methods. The study included 286 patients (males and females aged >18 years with symptoms of congestive CHF of any etiology). The patients met at least two of the following inclusion criteria: dyspnea or orthopnea position, rales, peripheral edema, increased jugular pulsation, X-ray signs of congestion in pulmonary circulation, plasma BNP level >150 pg/ml or NT-proBNP >450 pg/ml. Each patient was evaluated for CHF data, demographic parameters, presence of concomitant diseases, echoCG and laboratory data, efficacy of drug therapy, and duration, control and outcome of inpatient treatment. Results. In the Bashkortostan Republic, ADCHF is more prevalent among men (mean age, 61±4.2 years) with the IIB stage of circulatory insufficiency according to the classification of N. D. Strazhesko and V. Kh. Vasilenko and III–IV NYHA FC. Concomitant diseases most frequently observed in patients with ADCHF syndrome included stage 3 essential hypertension, paroxysmal atrial fibrillation, type 2 diabetes mellitus, and chronic obstructive lung disease. The echoCG ejection fraction (EF) was 37.6±3.6%. In most cases, the multimodal therapy for ADCHF included ACE inhibitors, β-adrenoblockers, aldosterone antagonists, diuretics, and antiaggregants. With this therapy, survival time of patients was 92% for the follow-up period.
  1. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  2. Cleland JGF, Swedberg K, Follath F et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463.
  3. Арутюнов А. Г., Острая декомпенсация сердечной недостаточности и острая сердечная недостаточность – эволюция взглядов [Электронный ресурс]: Независимый международный информационно-образовательный портал «MedPro.ru», 2012. – Режим доступа: http://medpro.ru / groups / ostraya_dekompensatsiya_serdechnoi_nedostatochnosti_i_ostraya_serdechnaya_nedostatochnost_–_e / свободный. – Загл. с экрана. / Дата обращения – 12.11.2012.
  4. Беленков Ю. Н., Фомин И. В., Мареев В. Ю и др. Распро­страненность хронической сердечной недостаточности в Евро­пейской части Российской Федерации – данные ЭПОХА–ХСН (часть 2). Журнал Сердечная Недостаточность. 2006;7 (3): 3–7.
  5. Беленков Ю. Н., Мареев В. Ю., Арутюнов Г. П., Агеев Ф. Т. Национальные рекомендации по диагностике и лечению ХСН. Журнал Сердечная недостаточность 2003;4 (6):276–297.
  6. Summers RL, Amsterdam E. Pathophysiology of acute decompensated heart failure. Heart Fail Clin. 2009;5 (1):9–17.
Shepel R. N., Zakirova A. N. Evaluation of the syndrome of acute decompensated heart failure and concomitant diseases in patients residing in the Bashkortostan Republic. Russian Heart Failure Journal. 2013;14 (2):75-81

To access this material please log in or register

Register Authorize
Ru En